about MammaPrint
MammaPrint offers new options for breast cancer treatment
Current prognostic tools cause:
- Overuse of chemotherapeutic agents
- Underuse of chemotherapy on small tumours
- Inability to accurately predict long term prognosis
Now, MammaPrint can more accurately predict:
- Who may not require chemotherapy
- Which small tumours should be treated with chemotherapy
- 10 year survival
- 10 year risk of recurrence of metastases
MammaPrint is a gene expression profiling test that predicts the risk of metastasis in breast cancer patients. It is based on groundbreaking research performed at the Netherlands Cancer Institute and the Antoni Van Leeuwenhoek Hospital in Amsterdam, The Netherlands.
Note: MammaPrint analysis cannot be performed on formalin-fixed paraffin embedded (FFPE) tumor tissue as this fixation procedure causes the RNA to degrade. The high accuracy of MammaPrint depends on keeping the tumor RNA intact.